Therapeutic challenges in treating patients with fragile X syndrome and neoplasia

Andrew Farach, Laura S Farach, Arnold C Paulino

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The administration of cytotoxic therapy to patients with fragile X syndrome (FXS) presents several unique therapeutic challenges. The existence of fragile sites poses a theoretical risk of tumorigenesis and potentially increased treatment associated toxicity, however, controversy exists. We review the 42 previously reported cases of neoplasia in patients with FXS and report two novel neoplasms in patients treated with radiation therapy or combined chemoradiation. Our experience suggests that radiation therapy can be delivered safely in these patients without an expectation for increased acute/sub-acute normal tissue toxicity; however, treatment requires specialized facilities with the resources to deliver this care safely.

Original languageEnglish (US)
Pages (from-to)E153-6
JournalPediatric Blood and Cancer
Issue number12
StatePublished - Dec 2013


  • Child
  • Fragile X Syndrome
  • Humans
  • Male
  • Neoplasms
  • Young Adult
  • Case Reports
  • Journal Article
  • Review


Dive into the research topics of 'Therapeutic challenges in treating patients with fragile X syndrome and neoplasia'. Together they form a unique fingerprint.

Cite this